DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA. Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening. In XX. International Workshop on CLL (iwCLL 2023), Boston, USA. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening.
Authors DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA.
Edition XX. International Workshop on CLL (iwCLL 2023), Boston, USA, 2023.
Other information
Original language English
Type of outcome Konferenční abstrakta
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Organization Středoevropský technologický institut – Repository – Repository
Keywords in English CD20 antigen; rituximab; therapy of B-cell malignancies; CRISPR/Cas9 knockout screening
Links LX22NPO5102, research and development project. MUNI/A/1224/2022, interní kód Repo.
Changed by Changed by: RNDr. Daniel Jakubík, učo 139797. Changed: 27/3/2024 04:12.
Abstract
CD20 antigen has been used as a target of monoclonal antibodies (mAb) such as rituximab (RTX) in the therapy of B-cell malignancies for more than two decades. However, CLL B cells tend to express lower levels of CD20 on their surface or downregulate it following the mAb treatment, resulting in mAb resistance and subsequently therapy failure. Therefore, it is crucial to investigate the regulation of CD20 in order to restore sensitivity to anti-CD20 mAb and enhance its efficacy. The aim of this project was to perform genome-wide CRISPR/Cas9 knockout screening to identify genes whose disruption upregulates CD20 surface expression in the resistant cells with low CD20 levels.
Print
Add to clipboard Displayed: 12/7/2024 02:26